Floatz logo

Beam-201

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Stephan Grupp MD PhDPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the T-Cell Acute Lymphoblastic Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Sanofi
Phase 2B
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Isatuximab
Sanofi
Phase 2CCC
RANITIDINE
Sanofi
Phase 2CCC
Omacetaxine
First Affiliated Hospital of Zhejiang University
Phase 2CCC

View all 19 →

Same molecule, other indications

Beam-201 is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
lymphoblastic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
T lymphoblastic leukemia/lymphomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →